Warning: There are an increasing number of fraudulent websites that impersonate ESCMID Global. We would like to alert all our members and delegates to possible scams and we strongly advise you to use only the official ESCMID Global online registration for your bookings.
Abstract Categories 1a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance) 1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance) 1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance) 1d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts) 1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID) 1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV) 1g. Viral epidemiology – general, prevalence studies, molecular and genomic epidemiology (other than respiratory viruses, herpesviruses, hepatitis & HIV) 1h. Antiviral drugs, treatment, susceptibility/resistance (other than respiratory viruses, herpesviruses, hepatitis & HIV) 1i. Basic and applied virology (incl in vitro and in vivo models, novel methods) 1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact) 2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention) 2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host bio-markers, treatment and outcome prediction) 2c. Community-acquired respiratory infections (incl epidemiology, clinical features, imaging, treatment & prevention) 2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl epidemiology, clinical, imaging, treatment & prevention) 2e. Community acquired skin, soft tissue, bone & joint infections (incl epidemiology, clinical, imaging, treatment & prevention, excl prostheses) 2f. Community acquired nervous system and other multi-system bacterial infections (incl epidemiology, clinical, imaging, treatment & prevention) 2g. Zoonotic bacterial infections (incl foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR) 2h. Other intracellular or rare bacteria 3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives 3b. Resistance surveillance & epidemiology: Gram-negatives 3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB) 3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB) 3e. Resistance detection/prediction approaches (rapid and/or molecular assays, resistome analysis, inference methods) 3f. Clinical outcome of resistant infections (retrospective and prospective studies, excl clinical trials of new drugs) 3g. Spread of resistance (incl carriage, reservoirs, ecology, models, excl nosocomial transmission) 3h. Policy aspects of AMR (incl societal impact, economics, mitigation) 4a. Diagnostic bacteriology (incl culture based, traditional and general microbiology, serology, excl AST methods) 4b. Laboratory management (incl automation, data management, QC/QA, regulatory aspects) 4c. MALDI-TOF and other proteomic methods 4d. Molecular diagnostics (incl POCT and syndromic testing) 4e. Strain typing and surveillance (incl molecular, genomic and other advanced methods) 4f. Whole genome sequencing (incl pathogen characterisation, diagnostics, excl typing) 4g. Microbiome studies (incl clinical and diagnostic studies, One Health aspects) 4h. Clinical metagenomics 4i. Bioinformatics tools & pipelines 4j. Other novel diagnostic technologies 5a. Mechanisms of action & spectrum, new compounds, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics) 5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies) 5c. New or repurposed antibacterial agents: clinical studies and randomised trials 5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support/prediction tools, behavioural aspects) 5e. Safety, hypersensitivity and adverse effects of treatment 5f. Pharmacoepidemiology / pharmacoeconomics (incl cost-effectiveness, modelling, data tools) 6a. Fungal disease epidemiology 6b. Diagnostic mycology (incl traditional, molecular and other methods) 6c. Antifungal susceptibility testing & resistance (incl surveillance, mechanisms) 6d. Antifungal drugs & treatment (incl pre-clinical studies and clinical trials) 6e. Basic mycology (incl in vitro and in vivo studies, pathogenesis, virulence, mycobiome) 7a. Parasitic disease epidemiology 7b. Diagnostic parasitology (incl traditional, molecular and other methods) 7c. Antiparasitic susceptibility & drug resistance (incl surveillance, mechasnism) 7d. Antiparasitic drugs & treatment (incl pre-clinical studies and clinical trials) 7e. Travel medicine, migrant and refugee health 7f. Food & water safety, environmental health, vector epidemiology 7g. Global and public health & health security (incl policy-making, climate change, biosafety/biosecurity) 7h. Infections in low-resource settings (incl epidemiology, burden, health infrastructure, health disparities and vulnerable populations) 8a. Intravascular catheter-related infections (incl epidemiology, prevention) 8b. Other foreign-body and implant-associated infections (incl PJI) 8c. Surgical site infections 8d. Healthcare-associated pneumonia (incl VAP) 8e. Hospital epidemiology, transmission, surveillance & screening (incl hospital environment) 8f. Other healthcare associated infections (incl CDI, hospital outbreaks) 8g. Infection control interventions and trials (incl microbiota transplantation) 8h. Disinfection & biocides 8i. Healthcare workers and infection prevention (incl vaccination, protective equipment, behavioural aspects, training and practices) 9a. Microbial pathogenesis & virulence 9b. Host-pathogen interaction (incl basic microbiome studies, animal models) 9c. Pre-clinical biofilm studies 9d. Experimental and cellular microbiology 9e. Basic science studies using Omics (in vitro and in vivo ) 10a. Host genetics: susceptibility to infection & primary immunodeficiency 10b. Infections in immunocompromised hosts (incl epidemiology, clinical features, diagnosis, treatment, excl fungal infections) 10c. General vaccinology (incl in vitro and in vivo studies, policy, social aspects) 10d. Antiviral vaccines (excl influenza, respiratory and bloodborne viruses and COVID-19) 10e. Antibacterial vaccines 10f. Other preventive modalities (incl new vaccine technologies, antibody-based treatments) 10g. Immune response to infection (incl in vitro, animal and human studies, laboratory assessment of immunity and response, excl sepsis biomarkers) 11a. Professional affairs and career development 11b. Publishing, ethics, other academic affairs 11c. Medical education for CM/ID 11d. Digital health and infection (incl AI, data mining, informatics) 11e. Diversity and equality 11f. Advocacy and role of patients 12a. Viral infections 12b. Bacterial infections 12c. Fungal infections 12d. Parasitic infections 12e. Other unusual clinical situations
